A mysterious and deadly virus has captured global attention, prompting urgent travel warnings and widespread alarm. What is this untreatable illness that has everyone on edge? How did it originate, and why is it spreading so quickly?

What Is the Bleeding Eye Virus?

Known as the Marburg virus, the “bleeding eye” virus is a highly infectious pathogen that causes Marburg virus disease (MVD), a severe hemorrhagic fever in humans. It was first identified in 1967 during simultaneous outbreaks in Marburg and Frankfurt, Germany, and Belgrade, Serbia. These outbreaks were traced to African green monkeys imported from Uganda for research, resulting in several fatalities among laboratory workers and marking the virus’s alarming introduction to the human population.

Closely related to the Ebola virus, Marburg shares similar structural and symptomatic characteristics. Both viruses are filamentous, with single-stranded RNA genomes, and cause severe hemorrhagic fevers with high mortality rates. The virus’s natural host is the Egyptian fruit bat (Rousettus aegyptiacus), with human infections typically arising from prolonged exposure to caves or mines where these bats reside.

Transmission to humans occurs through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or animals. Human-to-human transmission is facilitated by contact with broken skin, mucous membranes, or contaminated surfaces and materials, such as clothing or bedding.

The World Health Organization (WHO) reports an average case fatality rate for MVD of around 50%, varying between 24% and 88% in past outbreaks depending on the virus strain and treatment. Currently, there are no approved vaccines or antiviral treatments for Marburg virus disease.

Recent Outbreak and Current Status of the Marburg Virus

Since the first recorded outbreak in 1967, MVD has primarily affected African nations. Recent outbreaks have been reported in Ghana (2022), Tanzania (2023), and, most recently, Rwanda.

In September 2024, Rwanda confirmed its first case of the Marburg virus, with 66 cases and 15 deaths reported as of November 29, 2024. The outbreak prompted the U.S. State Department to issue a travel advisory on November 22, urging travelers to exercise increased caution when visiting Rwanda. The advisory also highlighted the potential for additional health screenings for travelers entering and leaving the country.

Encouragingly, approximately 75% of reported cases in Rwanda have recovered, with the last known patient discharged on November 8, 2024, after testing negative for the virus. Following this, the WHO initiated a 42-day countdown on November 9, 2024, to declare the outbreak over if no new cases arise. If successful, this declaration is expected by December 22, 2024. Meanwhile, the Centers for Disease Control and Prevention (CDC) maintains a Level 2 travel advisory (Practice Enhanced Precautions) for Rwanda and continues to monitor the situation closely.

This latest outbreak underscores the ongoing threat posed by hemorrhagic fevers like Marburg. Vigilance, rapid response, and international collaboration are essential to managing such crises effectively.